Scott Byrd, Sudo Biosciences CEO (Frazier Healthcare Partners)
September 28, 2022 08:00 AM EDTUpdated 08:10 AM
Financing
Startups

Bris­tol My­ers got the first TYK2 ap­proval. Fra­zier’s new biotech Su­do hopes to get many more

Lei Lei Wu

News Reporter

Ear­li­er in Sep­tem­ber, the FDA ap­proved a TYK2 in­hibitor for the first time, a drug from Bris­tol My­ers Squibb for pso­ri­a­sis, with­out slap­ping on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times